Filtered By:
Drug: Velcade

This page shows you your search results in order of date.

Order by Relevance | Date

Total 70 results found since Jan 2013.

A Systematic Review of Second-Line Treatments in Antiviral Resistant Strains of HSV-1, HSV-2, and VZV
The objective of this study was to evaluate available literature on the possible efficacy of second-line treatments in HSV and the use of second-line treatments in HSV strains that are resistant to first-line treatments. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a final search was conducted in six databases on November 5, 2021 for all relevant literature using terms related to antiviral resistance, herpes, and HSV. Eligible manuscripts were required to report the presence of an existing or proposed second-line treatment for HSV-1, HSV-2, or varicella zoster virus (VZV...
Source: Herpes - April 12, 2023 Category: Infectious Diseases Authors: Kimberly C Lince Virgil K DeMario George T Yang Rita T Tran Daniel T Nguyen Jacob N Sanderson Rachel Pittman Rebecca L Sanchez Source Type: research

BDNF/TrkB confers bortezomib resistance in multiple myeloma by inducing BRINP3
CONCLUSIONS: BDNF/TrkB enhanced downstream pathway expression of phosphorylation STAT3 and BRINP3 molecules, promoting RPMI 8226/BTZ cell proliferating and survival.GENERAL SIGNIFICANCE: These data place BDNF/TrkB at the top of a pSTAT3-BRINP3 survival pathway and link adaptability to BTZ resistant conditions in MM disease.PMID:36565997 | DOI:10.1016/j.bbagen.2022.130299
Source: Biochimica et Biophysica Acta - December 24, 2022 Category: Biochemistry Authors: Li Bao Yutong Wang Minqiu Lu Lei Shi Bin Chu Shan Gao Source Type: research

Cancers, Vol. 14, Pages 5621: Guggulsterone Induces Apoptosis in Multiple Myeloma Cells by Targeting High Mobility Group Box 1 via Janus Activated Kinase/Signal Transducer and Activator of Transcription Pathway
. Bhat Shahab Uddin Multiple myeloma (MM) is a hematological disorder characterized by the abnormal expansion of plasma cells in the bone marrow. Despite great advances over the past three decades in discovering the efficacious therapies for MM, the disease remains incurable for most patients owing to emergence of drug-resistant cancerous cells. Guggulsterone (GS), a phytosteroid, extracted from the gum resin of guggul plant, has displayed various anticancer activities in vitro and in vivo; however, the molecular mechanisms of its anticancer activity have not been evaluated in MM cells. Therefore, in this study, we i...
Source: Cancers - November 16, 2022 Category: Cancer & Oncology Authors: Sabah Akhtar Lubna Zarif Shilpa Kuttikrishnan Kirti S. Prabhu Kalyani Patil Sabah Nisar Haissam Abou-Saleh Maysaloun Merhi Said Dermime Ajaz A. Bhat Shahab Uddin Tags: Article Source Type: research

Host Cell Neddylation Facilitates Alphaherpesvirus Entry in a Virus-Specific and Cell-Dependent Manner
Microbiol Spectr. 2022 Sep 29:e0311422. doi: 10.1128/spectrum.03114-22. Online ahead of print.ABSTRACTHerpes simplex virus 1 (HSV-1) commandeers the host cell proteasome at several steps of its replication cycle, including entry. Here we demonstrate that HSV-2, pseudorabies virus (PRV), and bovine herpesvirus 1 (BoHV-1) entry are blocked by bortezomib, a proteasome inhibitor that is an FDA-approved cancer drug. Proteasome-dependent entry of HSV-1 is thought to be ubiquitin-independent. To interrogate further the proteasomal mechanism of entry, we determined the involvement of the ubiquitin-like molecule NEDD8 and the neddy...
Source: Herpes - September 29, 2022 Category: Infectious Diseases Authors: Becky H Lee Giulia Tebaldi Suzanne M Pritchard Anthony V Nicola Source Type: research

Cancers, Vol. 14, Pages 1592: Targeting an MDM2/MYC Axis to Overcome Drug Resistance in Multiple Myeloma
Conclusion: Our findings provide a rationale for the therapeutic targeting of MDM2/c-Myc axis to improve clinical outcome of patients with refractory/relapsed MM.
Source: Cancers - March 21, 2022 Category: Cancer & Oncology Authors: Omar Faruq Davidson Zhao Mariusz Shrestha Andrea Vecchione Eldad Zacksenhaus Hong Chang Tags: Article Source Type: research

Metformin Relieves Bortezomib-Induced Neuropathic Pain by Regulating AMPKa2-Mediated Autophagy in the Spinal Dorsal Horn
Neurochem Res. 2022 Mar 12. doi: 10.1007/s11064-022-03571-7. Online ahead of print.ABSTRACTChemotherapy-induced neuropathic pain is a major clinical problem with limited treatment options. Here, we show that metformin relieves bortezomib (BTZ)-evoked induction and maintenance of neuropathic pain by preventing the reduction in the expression of Beclin-1, an autophagy marker, in the spinal dorsal horn. Application of rapamycin or 3-methyladenine, autophagy inducer and inhibitor, respectively, affected the mechanical allodynia differently. Co-application of 3-methyladenine and metformin partially inhibited the effect of metfo...
Source: Neurochemical Research - March 12, 2022 Category: Neuroscience Authors: Meng Liu Yu-Ting Zhao You-You Lv Ting Xu Dai Li Yuan-Chang Xiong Wen-Jun Xin Su-Yan Lin Source Type: research

Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis
CONCLUSIONS: This study identifies PYCR1 as a novel target in bortezomib-based combination therapies for MM.PMID:35105345 | DOI:10.1186/s13046-022-02250-3
Source: Cell Research - February 2, 2022 Category: Cytology Authors: Inge Oudaert Hatice Satilmis Philip Vlummens Wouter De Brouwer Anke Maes Dirk Hose Elke De Bruyne Bart Ghesqui ère Karin Vanderkerken Kim De Veirman Eline Menu Source Type: research

Bortezomib alleviates antibody-mediated rejection in kidney transplantation by facilitating Atg5 expression
J Cell Mol Med. 2021 Nov 3. doi: 10.1111/jcmm.16998. Online ahead of print.ABSTRACTAntibody-mediated rejection (AMR) is one of the most dominant mechanisms responsible for the loss of kidney grafts. Previous researches have shown that donor-specific antibodies (DSAs) are the major mediators of AMR. In order to prolong the survival time of grafts, it is vital to reduce the incidence of AMR and inhibit the generation of DSAs. We established an animal model of AMR by performing kidney transplantation in pre-sensitized rats. Then, we investigated the effect of bortezomib (BTZ) on AMR. We found that BTZ could reduce the serum l...
Source: J Cell Mol Med - November 4, 2021 Category: Molecular Biology Authors: Hong Cheng Bin Xu Lijie Zhang Yi Wang Ming Chen Shuqiu Chen Source Type: research

XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IkB
Transl Oncol. 2021 May 8;14(8):101114. doi: 10.1016/j.tranon.2021.101114. Online ahead of print.ABSTRACTAcross many cancer types in adults, upregulation of the nuclear-to-cytoplasmic transport protein Exportin-1 (XPO1) correlates with poor outcome and responsiveness to selinexor, an FDA-approved XPO1 inhibitor. Similar data are emerging in childhood cancers, for which selinexor is being evaluated in early phase clinical studies. Using proteomic profiling of primary tumor material from patients with high-risk neuroblastoma, as well as gene expression profiling from independent cohorts, we have demonstrated that XPO1 overexp...
Source: Translational Oncology - May 11, 2021 Category: Cancer & Oncology Authors: Basia Galinski Marcus Luxemburg Yosef Landesman Bruce Pawel Katherine J Johnson Stephen R Master Kevin W Freeman David M Loeb Jean M H ébert Daniel A Weiser Source Type: research